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Abstract
Background: HIV reservoirs are rapidly established after infection, and the effect of HAART initiated very early
during acute infection on HIV reservoirs remains poorly documented, particularly in tissue known to actively
replicate the virus. In this context, we used the model of experimental infection of macaques with pathogenic SIV
to assess in different tissues: (i) the effect of a short term HAART initiated at different stages during acute infection
on viral dissemination and replication, and (ii) the local concentration of antiviral drugs.
Results: Here, we show that early treatment with AZT/3TC/IDV initiated either within 4 hours after intravenous
infection of macaques with SIVmac251 (as a post exposure prophylaxis) or before viremia peak (7 days post-
infection [pi]), had a strong impact on SIV production and dissemination in all tissues but did not prevent infection.
When treatment was initiated after the viremia peak (14 days pi) or during early chronic infection (150 days pi),
significant viral replication persists in the peripheral lymph nodes and the spleen of treated macaques despite a
strong effect of treatment on viremia and gut associated lymphoid tissues. In these animals, the level of virus
persistence in tissues was inversely correlated with local concentrations of 3TC: high concentrations of 3TC were
measured in the gut whereas low concentrations were observed in the secondary lymphoid tissues. IDV, like 3TC,
showed much higher concentration in the colon than in the spleen. AZT concentration was below the
quantification threshold in all tissues studied.
Conclusions: Our results suggest that limited antiviral drug diffusion in secondary lymphoid tissues may allow
persistent viral replication in these tissues and could represent an obstacle to HIV prevention and eradication.
Background
The acute phase of human or simian immunodeficiency
virus (HIV/SIV) infections is decisive as it is character-
ized by a quick and strong decrease of T CD4+ memory
cells, particularly in the gut associated lymphoid tissue
(GALT), and a rapid spread of the virus in all lymphoid
tissues [1,2]. In a recent study, we have shown that dur-
ing acute SIV infection of macaques, the kinetics of viral
dissemination and replication differ between the differ-
ent lymphoid tissues. Following the peak of viremia,
viral DNA and RNA persist at high levels in the second-
ary lymphoid tissues (spleen and lymph nodes), whereas
they rapidly decrease in the blood and the gut [3].
Therefore, this study reinforces the need to explore not
only the blood, but also the different lymphoid tissues
when assessing strategies aimed at reducing SIV/HIV
reservoirs.
HAART initiated very early during infection could
prevent the loss of CD4+ T cells from the gut and may
delay the onset of the disease [4]. While HIV reservoirs
are also set up during acute infection, few studies have
focused on the effect of early HAART on tissue viral
replication and reservoirs.
Because of the difficulty to obtain tissue samples from
HIV infected patients, the macaque models are particu-
l a r l yu s e f u lf o rt h ee x p l o r a tion of viral dissemination
and replication in the different body compartments,
especially during the early phases of infection [5]. In the
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HAART initiated at different stages during SIV acute
infection on the viral burden in the main lymphoid tis-
sues, including the gut. Different quantitative
approaches were used, including total SIV-DNA to eval-
uate viral dissemination and SIV-RNA to assess viral
replication and production. As 2LTR SIV-DNA circles
have been suggested to accumulate in recently infected
target cells [6], we also explored the value of their quan-
tification as an additional method to assess the impact
of treatment on viral dissemination.
We show that the Zidovudine (AZT)/Lamivudine
(3TC) and Indinavir (IDV) combination could effi-
ciently reduce viral dissemination and replication in all
tissues when treatment was initiated before the peak of
viremia. Surprisingly, when the same treatment was
started after the viremia peak, the effect of treatment
w a ss t r o n g e ri nt h eg u tt h a ni nt h es e c o n d a r yl y m -
phoid tissues; this is likely due to the very heteroge-
neous tissue diffusion of several of the antiretroviral
drugs.
Results
A short term HAART initiated during early chronic SIV
infection reduces plasma viral load but has a weak effect
on secondary lymphoid tissues
In a first step, to validate our HAART treatment in the
SIV macaque model, we assessed the effect of the AZT/
3TC/IDV combination in chronically infected animals.
Six macaques infected with SIVmac251 were treated
with AZT/3TC/IDV twice a day after viral set point
(from day 150 pi). To determine the kinetics of viral
load decrease in different tissues, three of these animals
were killed at day 14 (chronic HAART 14d) and the
other three at day 28 (chronic HAART 28d) after the
onset of treatment. Three untreated animals at the same
stage of infection were used as controls (chronic
untreated). Among the HAART treated animals, one
(#20929) had undetectable PVL at the initiation of ther-
apy (day 0), but was nevertheless included in the analy-
sis since cell-associated viral load (CVL) in PBMC
evolved within the same range of the other treated
macaques.
We confirmed that in macaques chronically infected
with SIV, four weeks of HAART result in a decrease of
plasma viral load (PVL) similar to that observed in HIV-
infected patients receiving similar treatment [7]. As
early as day 14 of treatment, the PVL was reduced by
1.7 × log10 in geometric (G) mean, and three of these
animals had decreased PVL below detection threshold
(60 vRNA copies/ml) (Figure 1a). After 28 days of ther-
apy, only one macaque (#20828) had persistent viremia
which was slightly reduced when compared to day 0
(-0.9 × log10).
We then explored viral dissemination and replication
in PBMC, spleen, lymph nodes (LN) and the gut to
assess whether the decrease in plasma viral load reflects
similar dynamics in the other tissues. As previously
observed in patients infected with HIV, SIV-DNA in
PBMC was only slightly reduced by treatment, with G
mean reductions of 0.4 × log10 and 1.1 × log10 after 14
and 28 days of treatment, respectively (Figure 1b). Inter-
estingly, the level of SIV-DNA was not significantly
reduced in the lymph nodes and spleen of treated ani-
mals (Figure 1c). We surmised that the limited effect of
treatment in these tissues could be explained by the lim-
ited diffusion of antivirals in these compartments and/or
the inefficiency of the drug on long-lived infected cells.
In contrast, treatment had a strong effect in the diges-
tive tract with a G mean reduction of 1.8 × log10 in
colon (p = 0.049 at day 28). This tissue has predomi-
nantly short-lived CD4+ T cells facilitating the effect of
HAART [8]. Also, the antivirals may diffuse better in
these tissues.
We then measured levels of 2LTR SIV-DNA, as a
marker of recently infected cells as previously suggested
[6]. In untreated animals, we detected 2LTR SIV-DNA
in all the tissues studied. In macaques treated with
HAART for 28 days, levels of 2LTR SIV-DNA were sig-
nificantly reduced (p = 0.04) in the ileum when com-
pared to animals receiving only 14 days of HAART. On
the contrary, the antiviral treatment had no effect on
the 2LTR SIV-DNA levels in the LN and the spleen.
Although the value of 2LTR viral DNA circles is still
controversial, our result suggests that treatment prob-
ably affects efficiently the tissues with a predominance
of new infections (Figure 1d).
Finally, we measured SIV-RNA levels to assess the
production of SIV. Under treatment there is a significant
(p = 0.03) decrease of SIV-RNA levels if we consider all
compartments; but due to the limited number of ani-
mals in each group, the effect was not significant for
each tissue separately. The strongest effect was observed
in the gut, with a G mean decrease of 2.4 × log10 (Fig-
ure 1e), confirming the results observed for viral DNA
in the GALT. The effect of treatment on SIV-RNA
levels was more limited in the LN and spleen (G mean
decrease of tissue viral load: 1.8 × log10).
AZT/3TC/IDV treatment initiated before viremia peak
results in partial control of viral dissemination and
replication in tissues
When started during early chronic infection, a short
term HAART showed a limited and not significant
effect in LN and spleen. We then evaluated the effect of
this treatment initiated at earlier stages hypothesizing
that we might expect a better efficacy of HAART since
viral reservoirs are probably not yet fully established.
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Page 2 of 11In a first experiment, two groups of four SIV-
infected animals received AZT/3TC/IDV treatment or
a placebo starting 4 h after intravenous inoculation of
SIV. Animals were killed at day 14 pi, when viral
replication and dissemination were expected to be
maximal in placebo treated macaques (Figure 2a-e).
Confirming our previously published observations [9],
although early treatment could not prevent infection
after intravenous transmission, at day 14 pi, PVL and
CVL in HAART treated animals remained almost
undetectable (Figure 2a-b). Although levels of viral
RNA and DNA were close to the quantification
threshold, virus remained detectable in spleen and
mesenteric lymph nodes, confirming that residual SIV
replication and dissemination persisted despite
HAART was initiated very early (4h) after intravenous
inoculation of SIV.
In a second experiment, two groups of four SIV-
infected animals received AZT/3TC/IDV treatment or a
placebo between 7 and 21 days post-infection and were
killed at 21 days pi. In these animals, the effect of anti-
retroviral treatment was intermediate between what was
observed in macaques treated as early as 4 h pi and
macaques treated during early chronic infection. Thus,
the PVL at day 21 pi was significantly lower in HAART
treated animals than in placebo treated macaques (-2 ×
log10, p = 0.02), but no significant effect was found for
CVL (Figure 3a and 3b). (In the placebo group, animal
#14275 which displayed a controller profile was
excluded from statistical analysis). In almost all tissues,
a small but statistically significant decrease was observed
for SIV-DNA (p = 0.03 for spleen, peripheral LN,
mesenteric LN and colon) (Figure 3c). The treatment
also induced a significant decrease of 2LTR SIV DNA in
the spleen, the peripheral LN, and the colon (p = 0.03
for each tissue) (Figure 3d); while for SIV-RNA levels
the decrease was significant (p = 0.03) only in peripheral
LN (Figure 3e).
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Figure 1 Viral dynamics in SIV-infected macaques receiving a short-term HAART during early chronic infection. Among 9 SIV infected
macaques at the set point of infection (150 days pi), 3 animals were untreated and killed (chronic untreated: open symbols), 3 animals received
a 14 day long (chronic HAART 14d: black symbols) or a 28 day long (chronic HAART 28d: grey symbols) AZT/3TC/IDV treatment and were killed
at the end of treatment. In the blood, the treatment induced a decrease of the plasma viral load (a), but a weak impact on the cell associated
viral load (b). In tissue, total SIV DNA and 2LTR circles were almost constant in spleen and lymph nodes but reduced in gut (c, d). The treatment
reduced the SIV RNA level in all tissues, with a slightly more important decrease in the gut than in the spleen or LN (e). *: indicated a significant
difference (p < 0.05) using a Mann-Whitney test. ND: not determined due to the unavailability of ileum samples for placebo animals, LN: lymph
node, G mean: geometric mean. The grey area indicates the quantitative threshold of our qRT-PCR and qPCR assays.
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Page 3 of 11Initiation of AZT/3TC/IDV therapy after the viremia peak
results in limited and tissue-dependent effects on viral
replication and dissemination
We then addressed the issue whether similar effects
could be observed after maximal viral dissemination, at
at i m ew h e r ev i r a lr e s e r v o i r sa r ee x p e c t e dt ob ef u l l y
established. The same treatment was therefore initiated
(day 14 pi) just after viremia peak in a group of five
macaques. PVL, CVL, total SIV-DNA, 2LTR SIV-DNA
and SIV-RNA levels were determined 14 days later (day
28 pi) in different tissues and compared to levels of
three placebo animals also euthanized at day 28 pi.
In HAART treated animals, the effect of treatment
was limited. Plasma viral load was significantly lower
than in placebo macaques (p = 0.02) (Figure 4a). How-
ever, we did not observe any significant effect on CVL,
total SIV-DNA, 2LTR or SIV-RNA levels, in the spleen
or peripheral lymph nodes (Figure 4b-e). By contrast,
the three viral markers were reduced in the digestive
tract (Figure 4c-e), reminiscent of animals treated during
early chronic infection.
As for animals treated during early chronic infection,
the weak effect of HAART in spleen or peripheral LN
could be the consequence of the infection of long-lived
cells such as macrophages. In order to identify which
cell type sustained SIV production in secondary lym-
phoid tissues of HAART treated macaques, we charac-
terized SIV-RNA production using in situ hybridization
together with T cell staining with anti-CD3 antibodies.
In the spleen of placebo treated animals, SIV producing
cells were mainly CD3+ (black arrow, Figure 5a). Some
CD3-cells also produced weak quantities of SIV-RNA
(white arrow, Figure 5a). In HAART treated animals, we
confirmed the weak effect of treatment on SIV replica-
tion in the spleen with a number of SIV-RNA producing
cells equivalent to placebo animals. Similar to previous
observation of Cavert et al. in HIV infected patients
[10], SIV producing cells in the spleen of macaque
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Figure 2 Viral dynamics in SIV-infected macaques receiving a short-term post exposure HAART. Four hours after SIV intravenous
inoculation, 2 groups of 4 macaques received either the AZT/3TC/IDV combination (HAART 4h-d14) or a placebo (placebo d14), then were killed
at the end of treatment (14 days pi). After intravenous infection, post exposure HAART controlled the plasma (a) and the cell associated viral
load (b). In tissues collected 14 days after inoculation the viral dissemination (c) and replication (d, e) were almost undetectable in HAART 4h-
d14 animals (black symbols), whereas placebo d14 animals demonstrated extensive viral propagation (c) and replication (d,e) (open symbols). *:
indicated a significant difference (p < 0.05) using a Mann-Whitney test. LN: lymph node, G mean: geometric mean. The grey area indicates the
quantitative threshold of our qRT-PCR and qPCR assays.
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Page 4 of 11treated with HAART just after viremia peak were mainly
T cells and not macrophages as they generally express
CD3 (Figure 5b).
3TC concentrations vary with tissue and are inversely
correlated with viral load
As the persistent viral replication in secondary lym-
phoid tissues did not seem to be related to infection of
long-lived cells such as macrophages, we then hypothe-
sized that it could be linked to poor antiviral activity.
These could be due to either a poor diffusion of drugs
in the tissue, active efflux from target cells or reduced
nucleoside reverse transcriptase inhibitor (NRTI) phos-
phorylation by endocellular kinases. Drug pharmacoki-
netics (PK) can differ between species; however, we
have previously shown [11] that 3TC in macaques
treated with the same AZT/3TC/IDV combination
displays very similar PK to humans. Thus, we first
focused our measurements on the concentration of
3TC in different tissues of macaques treated with
HAART between days 14 and 28 pi. Consistent with
high impact of HAART on SIV replication in the gut,
we found the highest 3TC concentration in the diges-
tive tract (G mean 2 nM/10
6 cell equivalents (eq)
in colon). The concentration in the spleen was about
100 times lower (G mean: 0.017 nM/10
6 cell eq), and
the concentration in the peripheral LN was more than
300 times lower, than in colon (G mean: 0.006 nM/10
6
cell eq) (Figure 6a). Tissue cell concentrations of 3TC-
TP, the active form of the drug, varied in the same
way (Figure 6b); and transformation rates – calculated
by 3TC-TP concentration/3TC concentration – were
similar for each tissue tested (G means were 19.4 in
PBMC, 26.2 in spleen and 25.7 in peripheral LN), indi-
cating that efflux and phosphorylation of 3TC were
not the limiting factors of antiviral activity in the
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Figure 3 Viral dynamics in SIV-infected macaques receiving a short-term HAART before the viremia peak. Seven days after SIV infection,
4 macaques received either a placebo (placebo d21: open symbol) or the AZT/3TC/IDV combination (HAART d7-d21: black symbol) for 14 days
and were killed at the end of treatment (21 days pi). Initiation of HAART 7 days after SIV infection conducts to a significant decrease of PVL (a)
but non-significant reduction of CVL (b). Viral dissemination is also slightly (but significantly) impacted in almost all tissues (c), whereas viral
replication is only reduced in the spleen, peripheral LN and colon (d, e). Due to its controller profile, placebo animal #14275 was excluded from
statistical analysis. *: indicated a significant difference (p < 0.05) and t a trend (0.05 < p < 0.06) using a Mann-Whitney test. LN: lymph node, G
mean: geometric mean. The grey area indicates the quantitative threshold of our qRT-PCR and qPCR assays.
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Page 5 of 11different tissues. Interestingly, SIV-DNA level as indi-
cator of residual viral load in tissues was inversely
correlated (p < 0.01) with 3TC local concentration
(Figure 6c). Even though the correlation did not reach
statistical significance (p = 0,086), SIV-RNA level as
indicator of residual viral replication also seemed to be
inversely associated with 3TC local concentration
(Figure 6d). We also investigated the concentrations of
AZT and IDV in the same tissues. For AZT we found
concentrations below the quantification threshold in
almost all tissues explored (peripheral LN, spleen and
colon); this may be due to the short half-life of AZT
(data not shown). For IDV we found the same trend of
diffusion as for 3TC with much higher concentrations
in the colon (G mean: 102 pMol/10
6 cell eq) than in
the spleen (G mean: 0,094 pMol/10
6 cell eq, p < 0.05).
These results suggest that higher levels of residual viral
replication in peripheral LN and spleen result, at least
partially, from the low diffusion of antiviral drugs in
these tissues.
Discussion
We showed that a short term HAART can reduce viral
dissemination and replication in all tissues when
initiated very early after intravenous inoculation of SIV-
mac251, before the viremia peak. In animals treated just
after the initial viremia peak or during early chronic
infection, we observed significant differences in HAART
efficacy depending on the tissue considered. Maximum
inhibition occurred in the digestive tract of macaques.
These results are in accordance with those described in
humans showing a rapid and large decrease of viral
replication in GALT after successful HAART [12-15].
Although the GALT is considered today as the major
site of HIV replication, there are no data about local dif-
fusion of antiretroviral drugs in these tissues. The
dosages of 3TC and IDV we performed demonstrate, for
the first time, that two commonly used antiretrovirals
can diffuse very efficiently in the digestive tract, thus
probably explaining the high treatment efficacy observed
in this tissue. As we had recently shown [3], in the same
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Figure 4 Viral dynamics in SIV-infected macaques receiving a short-term HAART just after the viremia peak. Among 8 animals infected
since 14 days, 5 animals received the AZT/3TC/IDV combination (HAART d14-d28: black symbol) for 14 days whereas 3 animals received a placebo
(placebo d28: open symbol) for the same period. All the animals were killed at the end of treatment (28 days pi). HAART initiated at 14 days pi
conducted to a significant reduction of PVL (a) but a non significant decrease of CVL (b). Viral dissemination (c) and replication (d,e) were reduced
at different levels depending on the tissue considered: in the gut, the decrease was significant, whereas in spleen and peripheral LN, the viral
dissemination and replication were almost maintained. *: indicated a significant difference (p < 0.05) and t a trend (0.05 < p < 0.06) using a Mann-
Whitney test. LN: lymph node, G mean: geometric mean. The grey area indicates the quantitative threshold of our qRT-PCR and qPCR assays.
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Page 6 of 11SIV macaque model, the plasma viral load mainly
reflects the viral replication in the digestive tract. We
could therefore suppose that the rapid decrease in
plasma viral load observed after HAART initiation is
mainly due to the control of viral replication in the gut.
Despite a strong effect in the GALT, currently used
antiretroviral combinations are not sufficient to eradicate
t h ev i r u s .W et h e r e f o r ea s s u m ethat residual replication
in pharmacological sanctuaries and/or viral reservoirs
could provide an explanation to the incomplete success
of therapy. In patients treated with suboptimal regimens,
l i k et h eu s eo fo n l yt w oN R T I ,n os i g n i f i c a n tc h a n g e s
were observed in viral replication in LN or tonsils, even
after control of PVL [16-19]. Adding a protease inhibitor
(PI) increases the efficiency of treatment without achiev-
ing a full control of replication even in infected patients
with long term HAART [10,17,20,21].
Our results confirm in the SIV-infected macaque
model that HAART has limited impact on viral replica-
tion in secondary lymphoid tissues in spite of efficient
control of PVL or replication in the gut. Contrary to
Solas et al., who did not find any relationship between
PI levels and HIV RNA levels in the tissues [22], the
3TC dosages we performed showed for the first time
that low antiretroviral efficacy in spleen and peripheral
lymph nodes could be related to poor drug diffusion in
these organs, therefore favouring residual replication
and viral persistence.
Corroborating the data from Kinman et al.[ 2 3 ] ,w h o
showed very low diffusion of IDV in the lymph node of
macaque after oral administration, the very low level of
IDV measured in the spleen and peripheral lymph
nodes of treated macaques confirm that secondary lym-
phoid tissues could act as real pharmacological
sanctuaries.
Although one of the major limitations of our study is
that drugs have been administered during a short period
(14 to 28 days), several studies in humans indicate that
even after several years of HAART, viral mRNA is still
produced in peripheral lymph nodes. This confirms that
the poor drug diffusion we observed in lymph node and
spleen could provide a simple explanation to the
absence of virus eradication. As suggested by Stellbrink
[24], this residual replication in lymphoid tissues could
also permanently seed the latent reservoir.
In the central nervous system (CNS) and the testis,
the low levels of antiretroviral can be explained by poor
diffusion across the blood-brain or blood-testicular bar-
riers because of drugs efflux by ABC transporter
[22,25,26]. In the peripheral lymph node mononuclear
cells, we previously demonstrated a higher level of P-gp
mRNA expression than in PBMC [27]. However, we did
(b) (a) Spleen:  macaque 13514 (HAART d14-d28) – ISH SIV + IHC CD3 Spleen:  macaque  13927 (placebo d28) – ISH SIV + IHC CD3
Figure 5 SIV-producing cells in the spleen of SIV-infected macaques receiving a short-term HAART just after the viremia peak. SIV-RNA
detection in spleen section from a representative placebo d28 animal (#13927) (a) and a representative HAART d14-d28 animal (#13514) (b)
using
35S in situ hybridization and T cell staining with anti-CD3 antibodies. Black arrows indicate SIV+ CD3+ cells and white arrow SIV+CD3-cells.
Magnification: 200×.
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Page 7 of 11not observe here any differences in the ratios of 3TC
and 3TC-TP between the different tissues, indicating
that efflux from the cell or kinases activities are not the
limiting factors. It is therefore unlikely that P-gp activity
is involved in the poor diffusion of antiretroviral we
observed in secondary lymphoid tissues.
We also demonstrated that pharmokinetics and phar-
macodynamic parameters are important to consider
not only in the treatment of infected patients but also
in preventive approaches of HIV transmission like
post-exposure prophylaxis. After intravenous inocula-
tion of SIVmac251, infection could not be prevented
even if AZT/3TC/IDV combination was initiated
within a few hours, confirming our previous results
[9,28]. Recently [11] we have shown that the same
regimen prevents vaginal transmission of the same
virus, probably because of initial viral compartmentali-
zation and low dissemination [29] in association with
good diffusion of NRTI in the female genital tract [30].
Our results thus demonstrate the need to improve
antiretroviral biodistribution for better efficacy and
limitation of the pharmacological sanctuaries that
allow residual viral replication.
Conclusions
When initiated before the peak of viremia, a short-term
antiretroviral treatment can impact viral dissemination
and replication in almost all tissues. In this case, the
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Figure 6 3TC levels in tissues of SIV-infected macaques receiving a short-term HAART just after the viremia peak. 3TC and 3TC-TP were
measured in the tissues of macaque receiving the AZT/3TC/IDV combination between 14 and 28 days pi (HAART d14-d28). 3TC concentration
was high in the colon, 100 times lower in the spleen and 300 times inferior in peripheral LN (a). 3TC-TP showed the same trend in distribution
(b). Correlation between 3TC concentration and residual viral DNA (c) and RNA (d) in the lymphoid tissues showed an inverse relationship
between 3TC concentration and the residual viral load (c). *: indicated a significant difference (p < 0.05) using a Mann-Whitney test. G mean:
Geometric mean, Per LN: peripheral lymph node.
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Page 8 of 11treatment is more effective when initiated earlier. If the
identical treatment is started after the peak of viremia, or
during chronic infection, the effect of short-term HAART
seems to vary according to the tissue considered. In the
gut, where antiretroviral drugs diffuse easily, the viral bur-
den decreases rapidly; whereas in secondary lymphoid tis-
sues, poor diffusion of the antiviral drug could explain the
weak effect of treatment on the tissue viral load.
Methods
Animals, infections, treatment and tissue collection
We studied 33 young adult male cynomolgus macaques
(Macaca fascicularis), each weighing between 2.7 and
4.5 kg. Studies were conducted in accordance with
European guidelines for animal care and all experiments
were approved by the ethics committee for animal
experimentation “I l ed eF r a n c eS u d ” (Paris, France). All
macaques were inoculated intravenously with 50 AID50
of pathogenic SIVmac251 and divided into nine groups.
Six animals were treated with AZT (4.5 mg/kg) and
3TC (2.5 mg/kg) subcutaneously twice daily and indina-
vir (60 mg/kg), orally, twice daily. The treatment was
initiated after viral set point (day 150 pi) and the ani-
mals were killed after 14 days (chronic HAART 14 d
group) and 28 days (chronic HAART 28 d group) of
treatment. In parallel, 3 untreated animals were also
killed at 150 days pi (chronic untreated).
Four other animals received the AZT/3TC/IDV combi-
nation as early as 4 h post-infection and continued until
day 14 when the animals were killed (HAART 4h-d14
group). Four animals receiving a placebo in the same
conditions were also killed at 14 days pi (placebo d14).
A group of four animals received the same HAART
between days 7 and 21 pi (HAART d7-d21 group), then
the animals were killed on day 21 pi. Four animals
receiving a placebo in the same conditions were killed at
21 days pi (placebo d21).
In last group, 5 animals received the HAART treat-
ment between day 14 and day 28 pi and were killed on
day 28 (HAART d14-d28 group). Three animals receiv-
ing a placebo in the same conditions were killed at the
same time (placebo d28).
Immediately after killing the animals, tissue samples
from the spleen, peripheral lymph nodes (inguinal or
axillary) mesenteric lymph nodes, ileum and colon were
collected in quadruplicate and stored at -80°C. In order
to reduce the heterogeneous presence of lymphoid tis-
sue in the gut, we collected and processed large samples
for ileum and colon (250 to 400 mg).
Virological measurements in the blood
Plasma and cell-associated viral loads were determined
as previously described [9,31].
Virological measurements in the tissues
RNA and DNA extraction as well as quantification
of total SIV DNA, SIV 2 LTR circles and SIV RNA in
tissue were performed as previously described [3].
In situ hybridisation
SIV gag in situ hybridization combined with immunohis-
tochemistry for T cell markers was performed as pre-
viously described [32]. The specificity of the hybridization
signal was systematically checked by hybridizing sense
probes on successive sections. Image acquisition and ana-
lysis were performed on a Nikon i90 photomicroscope
using NIS-elements software.
Determination of antiretroviral concentration in tissues
3TC, 3TC-TP, AZT and IDV were assayed by liquid
chromatography coupled with tandem mass spectrome-
try (LC-MS/MS) or a modification of these methods, as
previously described [33-35].
Statistical analysis
Statistical analyses were carried out using Stat View soft-
ware (SAS institute Inc, Cary, North Carolina, USA).
Plasma and cell-associated viral load as well as SIV-RNA,
total SIV-DNA and 2LTR SIV-DNA were compared in
placebo and HAART-treated macaques using a nonpara-
metric Mann-Whitney test. Differences in 3TC and IDV
concentration in lymphoid tissues were assessed by the
same test. The correlation between 3TC concentration
and residual viral replication/load in tissue, were evalu-
ated using a nonparametric Spearman correlation test.
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